Bovine Herpesvirus 1 Infection Research Articles

Pneumonia Induced byEndobronchial Inoculation of Calves with Bovine Herpesvirus 1

Each of six calves inoculated endobronchially with bovine herpesvirus 1 (BHV-1) by means of a bronchoscope developed viral pneumonia. Gross and histopathological lesions were mainly localized to the right diaphragmatic lobe (middle to caudal region) of the lung and were closely associated with the site of the deposition of the inoculum. The lesions were characterized by intranuclear inclusion bodies associated with focal necrosis of the epithelium in the lower respiratory tract. BHV-1 antigen and BHV particles were detected in the degenerating bronchial, bronchiolar and alveolar epithelial cells. After infection, the total cell count in the broncho-alveolar lavage (BAL) fluid increased. In addition, BHV-1 antigen and virus were detected in the desquamated cells and macrophages of BAL fluid from the right diaphragmatic lobe, but not from the left diaphragmatic lobe. It is concluded that examination of BAL fluid is valuable for immunohistopathological and virological confirmation of BHV-1 infection.

A sensitive and specific PCR/Southern blot assay for detection of bovine herpesvirus 4 in calves infected experimentally

A PCR/Southern blot assay for detection of bovine herpesvirus 4 (BHV-4) in the background of bovine cellular DNA was developed. A BHV-4 specific sequence within the gene coding for the glycoprotein B (gB) was selected for primer sequences to guarantee the specificity of the assay. With a detection limit of six molecules BHV-4 DNA in the background of 1 μg of cellular DNA (equals about 150 000 bovine cells) this PCR/Southern blot assay represents a highly sensitive method for detection of BHV-4 DNA. At low concentrations of BHV-4 genomes, this assay also allows to estimate the copy number of BHV-4: a distinction between fewer than 6, 6–59 and more than 60 BHV-4 genomes/100 μl DNA suspension was possible. Tissue and blood samples of two calves, infected experimentally with BHV-4 were examined for the prevalence of BHV-4 DNA 130 days post infection. Ten days before taking samples, one of the calves was immuno-suppressed with dexamethasone. In both calves, BHV-4 DNA was detected in the leucocyte fraction of the blood, and beyond that in lower quantities in the spleen and the kidney of the immuno-suppressed calf. It is assumed that a latent BHV-4 infection was activated after application of dexamethasone and that the leucocyte fraction of the blood represents one site of latency of BHV-4 in cattle.

Evaluation of an immunofluorescent antibody test to detect bovine herpesvirus 1-specific IgM.

An indirect immunofluorescent antibody test (IIFAT) was developed to detect bovine herpesvirus 1 (BHV-1)-specific IgM. All sera were treated with protein-G agarose prior to testing to eliminate the possibility of false-positive results due to IgM-isotype rheumatoid factor (IgM-RF). Specific IgM was first detected 8 days after experimental infection of 3 calves free of maternally derived antibody, with peak responses occurring 2-7 days later. Seroconversion was detected in all 3 calves using a single-dilution enzyme-linked immunosorbent assay. Following reinfection at 30 days postinfection, a low-level IgM response was detected in only 1 calf. Seroconversion was detected in 2 calves. There was no evidence of activation of IgM-RF by infection or reinfection with BHV-1. When 87 acute and convalescent serum pairs collected from 21 outbreaks of respiratory disease were tested, specific IgM was detected in 58 animals (66.6%) from 19 (90.5%) outbreaks. Seroconversion was detected in 44 of these animals (50.6%) from 17 outbreaks (81.0%). The correlations between these 2 assays on a calf and outbreak basis were 79.3% and 90.5%, respectively. Specific IgM was detected in 17/20 sera (85.0%) collected from an additional outbreak. No virus was detected by virus isolation or immunofluorescent staining in nasal mucus samples collected at the same time. Detection of specific IgM by IIFAT is a useful technique for the serodiagnosis of BHV-1 infection.

Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1.

To determine the potential of replication-competent (E3-deleted) bovine adenovirus-3 (BAV-3) as a delivery system for vaccine antigens in calves, we evaluated the ability of recombinant BAV-3 expressing different forms of of bovine herpesvirus-1 (BHV-1) glycoprotein gD to protect against BHV-1 infection in calves that had pre-existing BAV-3 specific antibodies. Three- to four-month-old calves, vaccinated intranasally with recombinant BAV-3 expressing full-length gD (BAV3.E3gD) or a truncated version of gD (gDt) (BAV3.E3gDt), or with E3-deleted BAV-3 (BAV3.E3d; control), were challenged with BHV-1 strain 108. Vaccination with BAV3.E3gD or BAV3.E3gDt induced gD-specific antibody responses in serum and nasal secretions, and primed calves for gD-specific lymphoproliferative responses. In addition, all calves developed complement-independent neutralizing antibodies against BHV-1. Protection against viral challenge was observed in calves vaccinated with recombinant BAV3.E3gD or BAV3.E3gDt as shown by a significant reduction in body temperature and clinical disease, and a partial reduction in the amount and duration of virus excretion in nasal secretions. These results indicate that replication-competent BAV-3-based vectors can induce protective immune responses in calves (the natural host) that have pre-existing BAV-3-specific antibodies.

Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine

The efficacy and safety of a gene-deleted bovine herpesvirus-1 (BHV-1) vaccine was determined in a bovine herpesvirus challenge trial in calves. Three different doses of the vaccine were administered intramuscularly at 10 5, 10 6 and 10 7 PFU/ml and compared to a commercial vaccine and non vaccinated control calves. Challenge was performed by intranasal aerosolization with the Cooper strain of BHV-1 (3×10 4 PFU/ml). The non-vaccinated calves shed significantly ( P<0.05) more virus than all other groups on days 4, 8 and 10 post challenge. By day 14 post challenge, antibody titers for BHV-1 of calves vaccinated with 10 7 PFU/ml were significantly ( P<0.05) higher than the commercial or non-vaccinated calves. Clinical scores of non-vaccinated calves were significantly ( P<0.05) higher than all other groups on days 4–14 post challenge. With both radioimmunoprecipitation and competitive enzyme-linked immunosorbent assays (C-ELISA), calves in the gene-deleted vaccine groups mounted comparable specific responses against gB, gC and gD post vaccination as calves in the commercial vaccine group, but in a dose dependent manner. These data suggest that the gene-deleted BHV-1 vaccine tested may be used as an effective vaccine in controlling BHV-1 infections.

Cloning and expression of bovine herpesvirus-1 glycoprotein C.

Glycoprotein C (gC) of Bovine Herpesvirus-1 (BHV-1) is expressed at high levels on surface of infected cells and on virus envelope. It is relatively immunodominant in antibody response to BHV-1 infection and protective in immunized bovines against BHV-1 challenge. In an attempt to express gC in mammalian cells, the 2.4 kb BamHI-EcoRI fragment, containing complete coding sequence of the gC gene was excised from a recombinant plasmid and cloned under the control of RSV-LTR. The resultant plasmid pRSV-gC was transfected into MDBK cells and expression of gC was detected by indirect immunofluorescence. The non-permeabilized cells revealed surface expression of gC.

Milk production and reproduction during a subclinical bovine herpesvirus 1 infection on a dairy farm

This study describes an outbreak of bovine herpesvirus 1 (BHV1) infections in a dairy herd with special reference to disease symptoms, reproductive performance and milk production losses. The study was carried out with a dairy herd consisting of 98 lactating animals. All animals were housed in the same freestall barn with intensive contact between all animals. An outbreak of BHV1 was induced by injecting three seropositive cows with dexamethasone. During the outbreak, no clinical signs were observed in any of the newly infected animals. At the time of infection, a significant drop in milk production was noted in animals that were initially-seronegative. The production loss was estimated at approximately 9.5 l per infected animal during the infectious period of 14 days. None of the pregnant cows aborted because of BHV1 infection. During 50 days before BHV1 circulation, there was a significant decrease in the number of successful inseminations in both seronegative and seropositive animals. Therefore, it is doubtful that early pregnancies were terminated by BHV1 infection. The proportion of successful inseminations during the BHV1 circulation in this herd, and in the period thereafter, did not significantly differ from the baseline period.

An association exists between bovine herpesvirus-4 seropositivity and abortion in cows

The prevalence of cattle seropositive to bovine herpesvirus-4 (BHV-4) is high in Belgium. In Belgian farms, clinical signs associated with BHV-4 infection essentially involve the genital tract and consist mainly of postpartum metritis or metroperitonitis. The role of BHV-4 in abortion has not been definitively demonstrated but epidemiological and experimental facts suggest its involvement. A seroepidemiological investigation was therefore conducted as a case-control study to compare the seroprevalences of BHV-4 infections in the aborted-cow population and in a randomly selected control group in the province of Liège (Belgium). The seroprevalence (17.2%) in aborted cows was significantly higher than that of the control group (10.0%). The odds ratio (OR) was 1.87 (1.06 < 3.30). BHV-4 infection is therefore considered as a risk factor for abortion in cows.

Bovine herpesvirus-1 infection affects the peptide transport activity in bovine cells

Infection of cattle with bovine herpesvirus-1 (BHV-1) impairs the cell-mediated immune response (CMI) of the affected host. We investigated the location of interference of BHV-1 with the major histocompatibility complex (MHC) class I antigen presentation pathway by employing an assay that allows assessment of the peptide transport activity of the Transporter associated with Antigen Presentation (TAP) from the cytoplasm into the endoplasmic reticulum (ER). We found a considerable down-regulation of the peptide transport activity in bovine epithelial cells, taking place as early as 2 h after virus infection. This down-regulation was also dose-dependent, and, at high multiplicities of infection (moi), led to an almost complete shutdown of TAP. By inhibiting peptide transport into the ER, the virus impairs loading of MHC class I molecules and their subsequent egress from the ER to the cell surface. This may lead to defective priming of cytotoxic T lymphocytes. Thus, BHV-1 is yet another member of its family Herpesviridae that selectively interferes with the host's antigen presentation machinery to evade the host's immune response in vivo.

Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV

A gE-negative bovine herpesvirus 1 (BHV1) vector vaccine carrying a gene coding for the G protein of bovine respiratory syncytial virus (BRSV) BHV1/BRSV-G) induced the same high degree of protection in calves against BRSV infection and BHV1 infection as a multivalent commercial vaccine. A DNA plasmid vaccine, carrying the same gene as the BHV1/BRSV-G vaccine, significantly reduced BRSV shedding after BRSV infection compared with that in control calves, but less well than the BHV1/BRSV-G vaccine. Flow cytometric analysis showed a significant relative increase of γ δ + T cells in peripheral blood after BRSV challenge-infection of the calves of the control group but not in the vaccinated groups. These results indicate that the G protein of BRSV can induce significant protection against BRSV infection in cattle, and that the BHV1/BRSV-G vaccine protects effectively against a subsequent BRSV and BHV1 infection.

A Molecular Genetic Approach to Improved Animal Health: The Effect of Interferon Genotype on the Severity of Experimental Bovine Herpesvirus-1 Infection

In the past decade, biotechnology has brought veterinary medicine an increased understanding of the effects of genetic background on disease resistance and production traits. Specific point mutations have been identified for a number of genetic diseases and genetic testing; selective breeding programs can eliminate these diseases from the population. Complex traits such as disease resistance and production traits are thought to be under the control of multiple genes, making their manipulation more difficult. Because of their antiviral and immune modulating properties, interferons may be a role in the host defense against viral infection. The Type I interferon gene family has been detailed in cattle and consists of approximately 32 genes clustered together on bovine chromosome 8. These genes are very polymorphic in the population, enabling studies on the association between alleles at specific interferon loci and the severity of clinical diseases following experimental Bovine Herpesvirus-1 infection. Associations were observed between specific IFN genotypes and increased severity of clinical disease in a population of unrelated cattle. With a better understanding of IFNs at the genetic level, it may eventually be possible to manipulate the IFN response for the therapeutic benefit of cattle, and lessen the economic impact of specific diseases on cattle producers.

Bovine herpesvirus-1 infects activated CD4+ lymphocytes.

Acute virus infections can induce immune deficiencies, as shown by immunosuppression to a variety of antigens and mitogens. Previously we observed that live bovine herpesvirus-1 (BHV-1) induced considerable lymphocyte death in culture, suggesting that the virus infected one or more cell populations. Our goal was to identify the cells infected by BHV-1 and the mechanism resulting in cell death. ConA activated cells were cultured with BHV-1 and stained with monoclonal antibodies specific for virus envelope glycoproteins (gB, gC and gD) and lymphocyte surface proteins (CD2, CD4 and CD8) and a molecule associated with gamma/delta cells. Two-colour immunofluorescence revealed that virus glycoproteins were preferentially expressed on T lymphocytes of the CD4+ phenotype. Live virus was required for virus glycoprotein expression, and by 48 h considerable loss of CD4 expression was observed. To confirm virus replication, RNA was isolated from cells, reverse transcribed and amplified using primers to a 342 bp region of immediate-early and early genes (IER2.9/ER2.6) or a 392 bp region of an early gene (gD). Immediate-early/early gene products were detected in CD4+T lymphocytes but not in infectious virions. Lymphocyte apoptosis was observed by 7 h post-infection with increasing levels of cell death at 24-48 h after infection. These findings suggest that the loss of proliferating CD4+ T cells during infection or vaccination with modified live vaccines provides the opportunity for secondary infections that commonly occur following BHV-1 infection.

A serological survey of bovine herpesvirus-1 infection in selected dairy herds in northern and central Italy

Serum samples from a total of 6979 dairy cattle from 55 herds in northern Italy (51 herds) and central Italy (4 herds), were examined by the serum neutralization test for the presence of antibody to bovine herpesvirus-1 (BHV-1). It was found that 84.31% of the farms selected in northern Italy and all the farms from central Italy had seropositive animals at titers of 1:4 or higher. The prevalence of infection was essentially the same among the cattle populations of the two selected areas of the country, being of 34.99% in the north and of 38.65% in central regions. A comparison of the data from the present study with those obtained in a serological survey conducted in Italy in 1966, shows that the rate of seropositive cattle to BHV-1 has increased by about 5.0% in the last 30 years.

Yeast-secreted bovine herpesvirus type 1 glycoprotein D has authentic conformational structure and immunogenicity

Bovine herpesvirus-1 (BHV-1) glycoprotein D (gD), an envelope glycoprotein, engenders mucosal and systemic immunity protecting cattle from viral infection. Production of gD with authentic immunogenicity is required for a subunit vaccine. We placed the truncated BHV-1 gD gene, lacking its putative transmembrane and cytoplasmic domains, under the control of the methanol-inducible AOX1 promoter in the yeast Pichia pastoris. Truncated BHV-1 gD (tgD) was efficiently secreted into the culture medium as a 68 kDa protein using either the yeast alpha prepro or native BHV-1 gD signal sequences. The yeast-secreted tgD had N-linked glycosylation and appears to have authentic conformational structure and immunogenicity based on the following observations. A panel of monoclonal antibodies recognizing five neutralizing epitopes reacted with yeast tgD. Sera from yeast tgD-immunized mice immunoprecipitated native BHV-1 gD and neutralized BHV-1 infection in vitro. Yeast tgD competitively blocked all reaction between native gD and monospecific gD polyclonal sera from cattle. Based on these data, yeast-derived BHV-1 tgD is an excellent candidate for a subunit vaccine.

A quantitative study of the efficacy of a deletion mutant bovine herpesvirus-1 differential vaccine in reducing the establishment of latency by wildtype virus

Using quantitative polymerase chain reaction (PCR) we have studied the latency established by wildtype (WT) bovine herpesvirus-1 (BHV-1) after challenge of cattle that had been vaccinated with a double deletion (gC-ltk-) mutant BHV-1 vaccine. Fourteen animals were vaccinated intramuscularly with 2 ml containing 10 7.4 CCID 50 (cell culture infectious dose 50%) of IBRV(NG)dltkdlgC and challenged, along with six unvaccinated control animals, 30 days later with 10 8.2 CCID 50 of WT BHV-1 (Cooper). The ability of this vaccine to prevent acute clinical BHV-1 infection after this challenge has been previously reported 1. Sixty days after challenge, eight of the vaccinates and the six control animals were euthanitized and the trigeminal ganglia (TG) examined for the amount of WT BHV-1 DNA by an internal standard quantitative PCR. The quantitative protocol that we used is based on co-amplification of BHV-1 gC specific sequences (present in WT BHV-1 but absent in the vaccine strain) and sequences from the bovine growth hormone (BGH) gene, which is used as an internal standard. The TG of the eight vaccinates contained BHV-1 WT DNA, but in a statistically significantly lower amount than the unvaccinated controls. These results are significant from the standpoint that, to our knowledge, this is the first report of a systematic quantitative approach to the study of the effect if BHV-1 vaccines on latency.This technique could be used to measure and compare the efficiency of various BHV-1 vaccines in preventing or diminishing latency, which is a significant factor for the perpetuation of BHV-1 in cattle populations.

Assessment of the cell-mediated immunity in cattle infection after bovine herpesvirus 4 infection, using an in vitro antigen-specific interferon-γ assay

The cell-mediated immunity (CMI) following bovine herpesvirus 4 (BHV4) infection has been poorly investigated in cattle. The in vivo response measured by a delayed type of hypersensitivity (DTH) assay has been reported to be positive in only few animals showing serological evidences of BHV4 infection. We have investigated the CMI following BHV4 infection by an in vitro antigen-sepcific interferon gamma (IFN-γ) release assay, as an indicator of an actively acquired immunity to BHV4. Our preliminary results using a partially purified antigen suggest that there was a measurable CMI in 75 out of 168 animals (44.4%) originating from a farm with a clinical history and serological evidences (76.3% seropositivity) of BHV4 infection. If the results of serological tests and BHV4 IFN-γ test are interpreted in parallel, 81.5% of the animals are classified positive, demonstrating the complementarity of these tests. The specificity of the BHV4 IFN-γ test was supported by the absence of a measurable CMI in 41 animals originating from a farm with no clinical history or serological evidence of BHV4 infection. In an allied study, we developed a bovine herpesvirus 1 (BHV1) IFN-γ test. This allowed us to measure the antigen specific IFN-γ release after stimulation with a mixture of BHV1 and BHV4 antigens. Animals that were classified negative by the BHV4 IFN-γ test and by the BHV1 IFN-γ test, were classified negative after stimulation with a mixture of both antigens. Animals that were classified positive by the BHV4 IFN-γ test or the BHV1 IFN-γ test, were classified positive after stimulation with a mixture of both antigens. Taken together these results suggest that the in vitro assessment of the CMI after BHV4 infection should be further investigated as a specific and valuable alternative to the DTH assay.

A European inter-laboratory trial to evaluate the reliability of serological diagnosis of bovine herpesvirus 1 infections

The detection of cattle latently infected with bovine herpesvirus 1 (BHV1) is of importance in control programs and in international trade activities. Therefore, tests to detect specific antibodies in serum must be highly sensitive. To evaluate the reliability of serological diagnosis of BHV1 infections in Europe, seventeen laboratories in 15 European countries were asked to determine BHV1-specific antibodies in a panel of bovine serum samples using the serological tests available in their laboratory. Laboratory tests included virus neutralisation tests (1, 2 and 24 h), indirect immunofluorescence tests and ELISAs. The serum panel consisted of 12 duplicate lyophilised samples which were randomly coded from 1 to 24 and included negative, weak- and strong-positive samples as well as international reference sera. Virus neutralisation tests and ELISAs showed a high specificity. All participants using neutralisation tests ( n = 13) scored the negative samples correctly. Twenty three of 25 ELISAs showed 100% specificity. A serum sample obtained at day 7 after infection was scored as negative by all tests except one home-made blocking ELISA. Samples obtained at day 9 and at day 11 after infection were scored as positive by approximately half and by all tests, respectively. To score the weak-positive European reference standard (EU2) correctly, 24 h neutralisation tests (positive by 8 of 9 laboratories) and home-made blocking ELISAs (positive by 5 of 6 laboratories) were the most reliable. The results indicate that standardisation is urgently needed to ensure that BHV1-infected animals with low antibody titres are recognised.

Effect of recombinant bovine interleukin-1 beta in normal calves and in calves infected with bovine herpesvirus type 1.

Bovine herpesvirus-1 (BHV-1) is an important pathogen of respiratory infections in cattle. Its continuing importance lies in its ability to predispose infected hosts to bacterial infections. In this present study, we determined whether the immunoregulatory effects induced by interleukin-1 (IL-1) could stimulate appropriate host defense mechanisms to influence the course of BHV-1 infection in cattle. We first evaluated the effect of different doses (10-1000 ng/kg) of IL-1 in normal cattle. A single administration of IL-1 was able to induce a dose-dependent increase in polymorphonuclear (PMN) cells as well as monocytes in peripheral blood. The number of CD3+ lymphocytes and gamma/delta T cells in peripheral circulation decreased transiently in a dose-dependent manner. In the disease model, the effect of IL-1 administration (300 ng/kg) 24 h before, at the time of, and 24 h after the BHV-1 challenge was assessed. As a single therapeutic modality, IL-1 did not significantly reduce the establishment or progression of BHV-1-induced disease. Nevertheless, our results demonstrated that the significant modulation of diverse immune parameters did not exacerbate disease. Thus, the use of IL-1 as an adjunct therapy or as a vaccine adjuvant in cattle can be safely considered in situations where BHV-1 infection is likely to occur.

Establishment of a rabbit model for bovine herpesvirus type 5 neurological acute infection

This study was conducted to evaluate the suitability of the rabbit as a model for bovine herpesvirus 5 (BHV-5) acute infection. In a preliminary experiment, a total of 24 one-month old New Zealand white rabbits were inoculated with BHV-5 or bovine herpesvirus 1 (BHV-1) by the intraconjunctival, intracerebral or intranasal routes. BHV-5 or BHV-1 inoculated in the conjunctiva induced virus proliferation in the eye mucosae and the nasal cavity of rabbits without meningo-encephalitis. On the other hand, only BHV-5 infection by intranasal or intracerebral routes produced a fatal meningo-encephalitis. The intranasal route was used in a further experiment for the establishment of a rabbit model for BHV-5 infection. A total of 45 rabbits were inoculated intranasally with BHV-5 or BHV-1. The results showed that intranasal inoculation of BHV-5 strain N569 in rabbits was followed by the development of a lethal meningo-encephalitis for 66% of rabbits while all BHV-1 infected rabbits remained healthy throughout this experiment (28 days). Analysis between the mortalities of rabbits infected with BHV-5 and BHV-1 were highly significant ( p < 0.001). The presence of BHV-5 in the central nervous system (CNS) was confirmed by virus isolation (essentially the cerebrum, midbrain and pons) and by immunohistochemical staining of BHV-5 antigen (essentially in the neurons of the cerebrum) only in BHV-5 infected rabbits showing clinical signs of meningo-encephalitis. The findings obtained confirmed the suitability of a rabbit model for the establishment of BHV-5 neurological acute infection and also as a valuable tool for the comparative study of BHV-5 and BHV-1 neuropathogenicity.

The latency-related gene of bovine herpesvirus 1 encodes a product which inhibits cell cycle progression.

Bovine herpesvirus 1 (BHV-1) establishes a latent infection in the sensory ganglionic neurons of cattle. The exclusive viral RNA expressed in a latent infection is the latency-related (LR) RNA, suggesting that it regulates some aspect of a latent infection. During the course of a productive infection, alphaherpesviruses induce certain events which occur during cell cycle progression. Consequently, we hypothesized that a BHV-1 infection might induce events in neurons which occur during cell cycle progression. In agreement with this hypothesis, cyclin A was detected in neurons of trigeminal ganglia when rabbits were infected. Neuronal cell cycle progression or inappropriate expression of cyclin A leads to apoptosis, suggesting that a viral factor inhibits the deleterious effects of cyclin A expression. The BHV-1 LR gene inhibited cell cycle progression and proliferation of human osteosarcoma cells. Antibodies directed against cyclin A or the LR protein coprecipitated the LR protein or cyclin A, respectively, suggesting that the two proteins interact with each other. We conclude that LR gene products inhibit cell cycle progression and hypothesize that this activity enhances the survival of infected neurons.